Physician profile

Jack D Summer

Internal Medicine · Washington, DC

NPI 1366514820

$2,145.14

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $276.37 2019-2020
Abbvie INC. $252.05 2019-2021
Lilly USA, LLC $224.03 2019-2021
Novartis Pharmaceuticals Corporation $186.43 2019
Kowa Pharmaceuticals America, INC. $165.08 2019-2020
Amarin Pharma, INC. $126.12 2019-2021
Regeneron Healthcare Solutions, INC. $105.86 2019
Allergan, INC. $98.39 2019-2020
Radius Health, INC. $94.69 2019
Novo Nordisk INC $69.99 2019-2020
Celgene Corporation $64.92 2019
E.R. Squibb & Sons, L.L.C. $62.06 2019
Glaxosmithkline, LLC. $57.13 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $45.04 2019
Astrazeneca Pharmaceuticals Lp $41.36 2019
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $38.94 2019
Janssen Pharmaceuticals, INC $38.79 2019
Ucb, INC. $37.67 2019
Horizon Therapeutics Plc $26.52 2019
Mallinckrodt Enterprises LLC $25.99 2019
Biohaven Pharmaceuticals, INC. $22.60 2021
Takeda Pharmaceuticals U.S.A., INC. $21.05 2019
Assertio Therapeutics, INC. $20.76 2019
Sanofi Pasteur INC. $19.24 2019
Pfizer INC. $12.51 2019
Arbor Pharmaceuticals, INC. $11.55 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jack D Summer

$2,145.14

in general payments reported 2019-2025

Years
2019-2021
Top company
Amgen INC.

https://glasscript.com/doctor/16241/jack-d-summer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.